Ennaid Therapeutics
Reino Unido
50 funcionários
Fundado em 2012
Descrição da empresa
Ver tradução
Ennaid Drug Development (EDD) is one of two subsidiaries of Ennaid Therapeutics. EDD is developing cures to help > 400 million people worldwide when infected with the mosquito-borne diseases, Zika virus and Dengue virus, the world’s fastest-growing pandemic. Ennaid Therapeutics strongly believes that there’s good, impactful science out there not being explored by big pharma beyond early laboratory tests, so they have chosen to fill a gap in which larger pharmaceutical companies typically may not focus. Hence, EDD acquires early-stage, proprietary, innovative science and creates an industry-accepted fast track development plan to bring first-to-market, profitable cures to the masses that disrupt rare & seemingly incurable diseases. Acquiring the best, most promising early-stage science to bring medicines, versus managing them is their passionate calling. Ennaid Drug Development (EDD) is one of two subsidiaries of Ennaid Therapeutics. EDD is developing cures to help > 400 million people worldwide when infected with the mosquito-borne diseases, Zika virus and Dengue virus, the world’s fastest-growing pandemic. Ennaid Therapeutics strongly believes that there’s good, impactful science out there not being explored by big pharma beyond early laboratory tests, so they have chosen to fill a gap in which larger pharmaceutical companies typically may not focus. Hence, EDD acquires early-stage, proprietary, innovative science and creates an industry-accepted fast track development plan to bring first-to-market, profitable cures to the masses that disrupt rare & seemingly incurable diseases. Acquiring the best, most promising early-stage science to bring medicines, versus managing them is their passionate calling. The first such promising scientific technology that EDD acquired was from Florida Gulf Coast University in Fort Myers, FL and The University of Washington in Settle, WA and is a proprietary technology that shows > 99% effectiveness against flavivirus infectivity (both Zika virus and Dengue virus are flaviviruses). EDD’s fast track – development plan will safely and rapidly get these cures to market in record time. Some of the components of the proposed research include monitoring of distraction, impairment, fatigue, pain and perception levels. The proposed research also determines scan patterns, fixation and if driver is looking outside normal viewing parameters. Many of these components could be used for wheelchair applications. A number of areas of research and development would include the use of eye tracking to initiate other functions. A user could initiate wheelchair functions or other functions in environment around them. The end goal would be the integration of algorithms being development to recognize and classify hazards around a vehicle into a wheelchair. Imagine, a wheelchair that a user can drive or initiate in to self-drive to another room or location and once they arrive they can turn on lights or other functions. The major research questions that have to be answered include problems with eye tracking individual wearing glasses, different lighting testing of the technology installed on a wheelchair with special attention paid to transition and false triggers. Due to the physical circumstances of the users, they may be very sensitive to sudden movement, impact on other glitches. Key member of our team include: William Howe, VehWare CEO/former program manager optical systems at Pacific Missile Range Facility, Darnisha Grant Harrison, Ennaid Therapeutics Founder and CEO, Daryl Fleming PhD, VehWare CTO, Patrick Fleming PhD, VehWare Science advisor/ Professor at University of Notre Dame, Lijun Yin PhD, Binghamton. University and Robbie Walker, PhDc, Sr. Manager of Software Development, Ennaid Healthcare IT. The first such promising scientific technology that EDD acquired was from Florida Gulf Coast University in Fort Myers, FL and The University of Washington in Settle, WA and is a proprietary technology that shows > 99% effectiveness against flavivirus infectivity (both Zika virus and Dengue virus are flaviviruses). EDD’s fast track – development plan will safely and rapidly get these cures to market in record time. 72110 - Research and experimental development on biotechnology 72190 - Other research and experimental development on natural sciences and engineering 72200 - Research and experimental development on social sciences and humanities
Setor / Indústria{{industry.name}}
Produtos e Serviços
{{pas.productName}}
HS code: {{pas.hsCode | limitTo: 23}}
HS code: {{pas.hsCode | limitTo: 23}}
Mostrar mais
Contact this company through Start-Up Nation Central
Para entrar em contato com a equipe de suporte da ConnectAmericas, envie um e-mail para soporte@connectamericas.com e entraremos em contato em breve.
Seguir